Improving Treatments - Improving Lives


Veloxis Pharmaceuticals (Veloxis) is a speciality pharmaceutical company focused on the development and commercialization of Envarsus® (LCP-Tacro) for the prevention of organ rejection in kidney transplant patients. All clinical studies for Envarsus®, including two Phase III trials, have successfully been completed and a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in December 2013 seeking approval for the marketing and sale of Envarsus®. Envarsus® has been granted Orphan Drug Status by the FDA.



FEATURED EVENTS

Mar 3, 2015
Release of Annual Report 2014

PDF Veloxis Annual report 2014
 926.9 KB   Add to Briefcase
PDF Presentation
 404.1 KB   Add to Briefcase
Webcast Audiocast

To access the live conference call, please dial one of the following numbers:

+45 32 72 80 18 (Denmark)

+44 (0) 1452 555 131 (UK)

+1 866 682 8490 (USA)

Access code 88916362


Efforts to Obtain FDA Approval

Stock Information